World Acute Decompensated Heart Failure Forecast and Market Analysis to 2034

Dublin, April 13, 2018 (GLOBE NEWSWIRE) -- The "Acute Decompensated Heart Failure Forecast and Market Analysis to 2034" report has been added to ResearchAndMarkets.com's offering.

Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.

Recent events and opinion

• ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
• The author estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
• Natrecor and Simdax have had limited success in the highly genericized ADHF market.
• Discontinuations of ularitide and Reasanz have left the ADHF pipeline bare.

Key Topics Covered:

1 Treatment: Acute Decompensated Heart Failure (Published on 19 January 2018)

• Executive Summary
• Primary Research Methodology
• Disease Definition and Diagnosis
• Current Treatment Options
• Prescribing Trends

2 Epidemiology: Acute Decompensated Heart Failure (Published on 18 January 2018)

• Executive Summary
• Disease Background
• Sources And Methodology
• Forecast
• Epidemiologist Insight
• Strengths And Limitations
• Bibliography
• Appendix: Additional Sources

3 Marketed Drugs: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)

• Executive Summary
• Product Overview
• Diuretics
• Vasodilators
• Inotropic Agents
• Other Drug Classes
• Product Profile: NATRECOR
• Product Profile: SIMDAX

4 Pipeline: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)

• Executive Summary
• Clinical Pipeline Overview
• Recently Discontinued Drugs
• Product Profile (Late Stage): BMS-986231
  

For more information about this report visit https://www.researchandmarkets.com/research/gn65vq/world_acute?w=12

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology